FTH Faeth Therapeutics, Inc.
$37.45▼ -4.20%
Healthcare
Other
Volume 55.3K
Avg Volume (10D) 302.5K
Key Metrics & Fundamentals
Market Cap
$967.72M
P/E Ratio
–
Div Yield
–%
52W Range
7.45 - 42.14
% vs 50 MA
24.82%
% vs 200 MA
74.25%
RSI-14
62.2
MACD Histogram
+0.1000
Beta (1Y vs SPY)
1.79
Free Cash Flow
-$15.67M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.36M
COGS
–
Operating Exp
$18.39M
Operating Income
-$18.39M
EBIT
-$18.39M
Pretax Income
-$16.01M
Net Income
-$16.01M
EPS (Diluted)
-2.84
Price & Volume History
Loading chart…
Recent News
TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating
MT Newswires · Sep 9, 2026 12:09 PM
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Business Wire · Sep 8, 2026 11:30 AM
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Zacks · Sep 1, 2026 4:00 PM
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Business Wire · Sep 1, 2026 11:30 AM
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Aug 28, 2026 11:30 AM
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
Zacks · Aug 24, 2026 1:55 PM
Needham Initiates Faeth Therapeutics at Buy With $56 Price Target
MT Newswires · Aug 21, 2026 10:23 AM
Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination
MT Newswires · Aug 17, 2026 12:01 PM
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Business Wire · Aug 17, 2026 11:30 AM
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Business Wire · Aug 14, 2026 11:30 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See FTH's money flow as a full page
Social Sentiment
No Reddit posts found for FTH.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.